An Open-label, Multicenter, Efficacy and Safety Study of 4-month Canakinumab Treatment With 6-month Follow-up in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS)

Trial Profile

An Open-label, Multicenter, Efficacy and Safety Study of 4-month Canakinumab Treatment With 6-month Follow-up in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS)

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Cryopyrin-associated periodic syndromes
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2016 Results published in the Annals of the Rheumatic Diseases
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 19 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top